All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) smoker (current or former) smoker (Current) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
non squamous cell - mNSCLC - L1, anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpower-130 (all population), 2019 0.80 [0.65; 0.99]
IMpower-130 (WT), 2019 0.79 [0.64; 0.98]
IMpower-150 (ABCP vs BPC WT), 2018 0.78 [0.64; 0.96]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.76 [0.63; 0.92]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.85 [0.71; 1.02]
KEYNOTE-021, 2016 0.90 [0.42; 1.92]
KEYNOTE-189, 2018 0.49 [0.38; 0.64]
0.75 [0.66 ; 0.85 ] IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018, KEYNOTE-021, 2016, KEYNOTE-189, 2018 7 53% 4,439 moderate not evaluable deaths (OS) (extension)detailed results KEYNOTE-021, 2016 0.71 [0.45; 1.12]
KEYNOTE-189, 2018 0.56 [0.45; 0.70]
0.59 [0.48 ; 0.71 ] KEYNOTE-021, 2016, KEYNOTE-189, 2018 2 0% 739 low not evaluable PFS (extension)detailed results KEYNOTE-021, 2016 0.54 [0.35; 0.83]
KEYNOTE-189, 2018 0.48 [0.40; 0.58]
0.49 [0.41 ; 0.58 ] KEYNOTE-021, 2016, KEYNOTE-189, 2018 2 0% 739 low not evaluable progression or deaths (PFS)detailed results IMpower-130 (all population), 2019 0.65 [0.54; 0.78]
IMpower-130 (WT), 2019 0.64 [0.54; 0.76]
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 0.51 [0.38; 0.68]
IMpower-150 (ABCP vs BPC WT), 2018 0.62 [0.52; 0.74]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.61 [0.52; 0.72]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.91 [0.78; 1.06]
KEYNOTE-021, 2016 0.53 [0.31; 0.91]
KEYNOTE-189, 2018 0.52 [0.43; 0.63]
0.63 [0.55 ; 0.72 ] IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018, KEYNOTE-021, 2016, KEYNOTE-189, 2018 8 74% 4,719 moderate not evaluable DORdetailed results IMpower-130 (WT), 2019 2.41 [1.27; 4.60]
2.41 [1.27 ; 4.60 ] IMpower-130 (WT), 2019 1 0% 292 NA not evaluable objective responses (ORR)detailed results IMpower-130 (WT), 2019 2.07 [1.48; 2.89]
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 1.96 [1.20; 3.19]
IMpower-150 (ABCP vs BPC WT), 2018 1.88 [1.38; 2.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.95 [1.47; 2.58]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 1.02 [0.77; 1.35]
KEYNOTE-021, 2016 3.06 [1.45; 6.45]
KEYNOTE-189, 2018 3.88 [2.61; 5.79]
2.03 [1.47 ; 2.80 ] IMpower-130 (WT), 2019, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018, KEYNOTE-021, 2016, KEYNOTE-189, 2018 7 82% 3,970 moderate not evaluable objective responses (ORR) (extension)detailed results KEYNOTE-021, 2016 2.80 [1.34; 5.83]
KEYNOTE-189, 2018 3.84 [2.58; 5.70]
3.57 [2.52 ; 5.06 ] KEYNOTE-021, 2016, KEYNOTE-189, 2018 2 0% 739 low not evaluable AE (any grade)detailed results IMpower-130 (all population), 2019 2.05 [0.29; 14.63]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.49 [0.15; 1.65]
KEYNOTE-189, 2018 4.04 [0.36; 44.82]
1.17 [0.33 ; 4.18 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 3 36% 2,099 moderate not evaluable AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.72 [1.19; 2.47]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.14 [0.86; 1.52]
KEYNOTE-189, 2018 1.03 [0.73; 1.45]
1.25 [0.94 ; 1.67 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 3 56% 2,099 moderate not evaluable AE leading to death (grade 5)detailed results IMpower-130 (all population), 2019 0.94 [0.47; 1.87]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.10 [0.60; 2.03]
KEYNOTE-189, 2018 1.13 [0.56; 2.28]
1.06 [0.72 ; 1.55 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 3 0% 2,099 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpower-130 (all population), 2019 1.27 [0.88; 1.85]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.46 [1.07; 1.99]
KEYNOTE-189, 2018 2.19 [1.31; 3.65]
1.52 [1.17 ; 1.98 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 3 30% 2,099 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-189, 2018 2.04 [1.16; 3.59]
2.04 [1.16 ; 3.59 ] KEYNOTE-189, 2018 1 0% 607 NA not evaluable SAE (any grade)detailed results IMpower-130 (all population), 2019 1.69 [1.22; 2.32]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.40 [1.05; 1.87]
1.52 [1.23 ; 1.89 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,492 moderate not evaluable STRAE (any grade)detailed results IMpower-130 (all population), 2019 2.09 [1.35; 3.24]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.43 [1.02; 2.00]
KEYNOTE-021, 2016 3.47 [1.25; 9.62]
1.86 [1.24 ; 2.77 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 47% 1,613 moderate not evaluable STRAE (grade 3-4)detailed results KEYNOTE-021, 2016 5.56 [1.49; 20.67]
5.56 [1.49 ; 20.67 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable TRAE (any grade)detailed results IMpower-130 (all population), 2019 2.00 [1.01; 3.95]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.81 [0.43; 1.53]
KEYNOTE-021, 2016 0.95 [0.29; 3.12]
1.19 [0.63 ; 2.22 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 47% 1,613 moderate not evaluable TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.79 [1.28; 2.50]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.38 [1.04; 1.83]
KEYNOTE-021, 2016 2.04 [0.92; 4.52]
1.57 [1.27 ; 1.93 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,613 moderate not evaluable TRAE leading to death (grade 5)detailed results IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01]
KEYNOTE-021, 2016 0.52 [0.05; 5.86]
1.33 [0.61 ; 2.88 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,613 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-021, 2016 0.76 [0.25; 2.35]
0.76 [0.25 ; 2.35 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-021, 2016 4.44 [0.48; 40.91]
4.44 [0.48 ; 40.91 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 4.32 [0.19; 97.73]
4.32 [0.19 ; 97.73 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.06; 16.09]
KEYNOTE-189, 2018 0.50 [0.03; 8.00]
0.71 [0.10 ; 5.03 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 2 0% 1,394 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
0.80 [0.08 ; 7.74 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,613 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.62 [1.11; 2.36]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.05 [0.58; 1.89]
KEYNOTE-021, 2016 0.79 [0.27; 2.29]
1.30 [0.89 ; 1.90 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 22% 1,613 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.75 [0.17; 3.37]
0.75 [0.17 ; 3.37 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Asthenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.45 [0.15; 1.30]
0.76 [0.24 ; 2.44 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 48% 1,492 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.05 [0.02 ; 53.86 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.53 [0.49; 13.10]
KEYNOTE-189, 2018 3.01 [0.15; 60.33]
2.63 [0.62 ; 11.13 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 2 0% 1,394 moderate not evaluable Constipation TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.01 [0.12 ; 8.66 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,613 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.86 [0.25; 2.95]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.23 [0.43 ; 3.48 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,613 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
1.00 [0.08 ; 13.05 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 2 0% 1,394 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.03 [0.49; 2.14]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 5.64 [1.24; 25.63]
KEYNOTE-021, 2016 0.52 [0.02; 15.84]
1.71 [0.46 ; 6.33 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 53% 1,613 moderate not evaluable Dizziness TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.05 [0.02 ; 53.86 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
0.72 [0.04 ; 11.54 ] IMpower-130 (all population), 2019, KEYNOTE-021, 2016 2 0% 826 moderate not evaluable Epistaxis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59]
8.09 [0.43 ; 153.59 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.02 [0.53; 1.96]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.31 [0.57; 3.03]
KEYNOTE-021, 2016 4.32 [0.19; 97.73]
1.16 [0.70 ; 1.94 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,613 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.48 [0.85; 2.57]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
1.49 [0.87 ; 2.57 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 2 0% 908 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59]
KEYNOTE-189, 2018 4.02 [0.21; 76.41]
5.70 [0.71 ; 45.75 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 2 0% 1,394 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.57; 1.78]
1.00 [0.57 ; 1.78 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
1.09 [0.13 ; 9.35 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-189, 2018 3 0% 1,515 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
1.10 [0.08 ; 14.41 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 2 0% 1,394 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
1.70 [0.23 ; 12.33 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-189, 2018 3 0% 1,515 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
2.42 [0.43 ; 13.59 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 2 0% 908 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
2.42 [0.43 ; 13.59 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 2 0% 908 moderate not evaluable Increased lacrimation (TRAE grade 3-4)detailed results KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.05 [0.02 ; 53.86 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
1.45 [0.13 ; 16.15 ] KEYNOTE-021, 2016, KEYNOTE-189, 2018 2 0% 728 low not evaluable Leucopenia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.77 [0.51; 6.09]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
1.81 [0.56 ; 5.78 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 2 0% 908 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.18; 22.26]
2.01 [0.18 ; 22.26 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
1.10 [0.08 ; 14.41 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 2 0% 1,394 moderate not evaluable Nausea TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.61 [0.52; 5.00]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.91 [0.80; 4.57]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
1.81 [0.92 ; 3.55 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,613 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-189, 2018 6.06 [0.34; 109.04]
3.81 [0.42 ; 34.44 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 2 0% 1,394 low not evaluable Neutropenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.22 [0.86; 1.72]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.27 [0.83; 1.94]
KEYNOTE-021, 2016 2.14 [0.19; 24.25]
1.24 [0.95 ; 1.62 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,613 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.03 [0.18; 89.56]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
2.84 [0.32 ; 25.46 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-189, 2018 2 0% 1,394 moderate not evaluable Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 0.52 [0.02; 15.84]
0.52 [0.02 ; 15.84 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.50 [0.02; 14.97]
0.50 [0.02 ; 14.97 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01]
1.23 [0.50 ; 3.01 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.05 [0.02 ; 53.86 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 2.12 [0.07; 64.42]
2.12 [0.07 ; 64.42 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3.04 [0.61; 15.15]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
1.53 [0.60 ; 3.89 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016, KEYNOTE-189, 2018 3 0% 1,515 low not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.05 [0.02 ; 53.86 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Rash TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 10.14 [0.55; 186.27]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
5.25 [0.57 ; 48.07 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 2 0% 908 moderate not evaluable Sepsis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
2.06 [0.19 ; 22.93 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 2 0% 908 moderate not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
1.01 [0.33 ; 3.06 ] KEYNOTE-021, 2016, KEYNOTE-189, 2018 2 0% 728 low not evaluable Stomatitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
KEYNOTE-021, 2016 0.52 [0.02; 15.84]
2.22 [0.35 ; 14.07 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 2 0% 908 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.52 [0.83; 2.79]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.94 [0.47; 1.89]
KEYNOTE-021, 2016 1.05 [0.14; 7.73]
1.23 [0.79 ; 1.92 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,613 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.50 [0.01 ; 25.20 ] KEYNOTE-189, 2018 1 0% 607 NA not evaluable Vomiting TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.21 [0.37; 3.99]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
1.36 [0.58 ; 3.21 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, KEYNOTE-021, 2016 3 0% 1,613 moderate not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.23 [0.24; 6.38]
1.23 [0.24 ; 6.38 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Agranulocytosis (AE grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Alopecia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Anaemia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.47 [1.03; 2.11]
KEYNOTE-189, 2018 1.07 [0.67; 1.71]
1.30 [0.96 ; 1.76 ] IMpower-130 (all population), 2019, KEYNOTE-189, 2018 2 11% 1,312 moderate not evaluable Arthralgia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 7.97 [0.46; 139.30]
7.97 [0.46 ; 139.30 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Asthenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.59 [0.58; 4.39]
KEYNOTE-189, 2018 1.83 [0.78; 4.31]
1.73 [0.90 ; 3.32 ] IMpower-130 (all population), 2019, KEYNOTE-189, 2018 2 0% 1,312 low not evaluable Back pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
3.97 [0.49 ; 31.97 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Colitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 2.96 [0.15; 59.25]
2.96 [0.15 ; 59.25 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Constipation AE (grade 3-4)detailed results IMpower-130 (all population), 2019 4.95 [0.27; 90.93]
KEYNOTE-189, 2018 2.00 [0.22; 18.06]
2.78 [0.48 ; 16.08 ] IMpower-130 (all population), 2019, KEYNOTE-189, 2018 2 0% 1,312 low not evaluable Cough AE (grade 3-4)detailed results IMpower-130 (all population), 2019 2.96 [0.15; 59.25]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
1.53 [0.14 ; 16.60 ] IMpower-130 (all population), 2019, KEYNOTE-189, 2018 2 0% 1,312 moderate not evaluable Decreased appetite AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.33; 2.90]
KEYNOTE-189, 2018 3.02 [0.36; 25.28]
1.24 [0.47 ; 3.25 ] IMpower-130 (all population), 2019, KEYNOTE-189, 2018 2 0% 1,312 moderate not evaluable Diabetes mellitus AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.87 [0.44; 1.70]
KEYNOTE-189, 2018 1.79 [0.71; 4.50]
1.16 [0.58 ; 2.32 ] IMpower-130 (all population), 2019, KEYNOTE-189, 2018 2 34% 1,312 moderate not evaluable Dizziness AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dry skin AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 5.61 [1.31; 24.06]
KEYNOTE-189, 2018 0.67 [0.30; 1.48]
1.77 [0.22 ; 14.12 ] IMpower-130 (all population), 2019, KEYNOTE-189, 2018 2 84% 1,312 low not evaluable Epistaxis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Fatigue AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.28 [0.68; 2.43]
KEYNOTE-189, 2018 2.37 [0.89; 6.34]
1.55 [0.89 ; 2.70 ] IMpower-130 (all population), 2019, KEYNOTE-189, 2018 2 5% 1,312 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.90 [0.33; 2.46]
0.90 [0.33 ; 2.46 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Gastritis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Headache AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hypertension AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.30; 7.38]
1.48 [0.30 ; 7.38 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Increase AST AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.24; 3.96]
0.98 [0.24 ; 3.96 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.73 [0.20; 2.62]
0.73 [0.20 ; 2.62 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Lacrimation increased AE (grade 3-4)detailed results KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.50 [0.01 ; 25.20 ] KEYNOTE-189, 2018 1 0% 607 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.57 [0.66; 3.73]
1.57 [0.66 ; 3.73 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-14 13:32 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 307,165,163,176
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
